Autolus Therapeutics plc ADR [AUTL] stock is trading at $1.83, up 4.57%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AUTL shares have gain 2.23% over the last week, with a monthly amount drifted -17.19%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Autolus Therapeutics plc ADR [NASDAQ: AUTL] stock has seen the most recent analyst activity on November 18, 2024, when Goldman upgraded its rating to a Buy and also boosted its price target to $7.60 from $7. Previously, Redburn Atlantic upgraded its rating to Buy on November 15, 2024, and kept the price target unchanged to $13. On November 09, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $10 on the stock. Bryan Garnier initiated its recommendation with a Buy and recommended $5 as its price target on March 17, 2023. Jefferies upgraded its rating to Buy for this stock on June 14, 2021, and upped its price target to $12. In a note dated January 29, 2021, JP Morgan downgraded an Neutral rating on this stock but restated the target price of $9.
Autolus Therapeutics plc ADR [AUTL] stock has fluctuated between $1.68 and $6.62 over the past year. Currently, Wall Street analysts expect the stock to reach $7.6 within the next 12 months. Autolus Therapeutics plc ADR [NASDAQ: AUTL] shares were valued at $1.83 at the most recent close of the market. An investor can expect a potential return of 315.3% based on the average AUTL price forecast.
Analyzing the AUTL fundamentals
Autolus Therapeutics plc ADR [NASDAQ:AUTL] reported sales of 10.09M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -17.4%, Pretax Profit Margin comes in at -21.73%, and Net Profit Margin reading is -22.77%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.64 and Total Capital is -0.27. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7367 points at the first support level, and at 1.6433 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8867, and for the 2nd resistance point, it is at 1.9433.
Ratios To Look Out For
For context, Autolus Therapeutics plc ADR’s Current Ratio is 13.64. In addition, the Quick Ratio stands at 13.64 and the Cash Ratio stands at 12.52. Considering the valuation of this stock, the price to sales ratio is 48.27, the price to book ratio is 1.02.
Transactions by insiders
Recent insider trading involved Martin Pule, Officer, that happened on Sep 16 ’24 when 0.7 million shares were purchased.
